Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of Exelixis from a hold rating to a buy rating in a research report on Friday, June 23rd. SunTrust Banks, Inc. started coverage on shares of Exelixis in a research note on Thursday, July 13th. They set a buy rating and a $33.00 target price on the stock. Piper Jaffray Companies reaffirmed a buy rating and set a $29.00 target price on shares of Exelixis in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Exelixis from a strong-buy rating to a hold rating in a research note on Wednesday, June 28th. Finally, Cann reaffirmed a hold rating on shares of Exelixis in a research note on Wednesday, April 19th. Five investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $25.57.
Shares of Exelixis (EXEL) opened at 26.33 on Monday. The stock has a market capitalization of $7.74 billion, a PE ratio of 132.98 and a beta of 1.89. Exelixis has a 12 month low of $10.04 and a 12 month high of $28.45. The stock’s 50 day moving average is $26.48 and its 200 day moving average is $22.58.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. Exelixis’s quarterly revenue was up 173.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. Analysts anticipate that Exelixis will post $0.26 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/exelixis-inc-nasdaqexel-upgraded-at-thestreet-updated.html.
In other news, insider Patrick J. Haley sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total value of $92,300.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.10% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in EXEL. Fortaleza Asset Management Inc. bought a new stake in Exelixis during the first quarter worth about $106,000. First Quadrant L P CA bought a new stake in Exelixis during the second quarter worth about $144,000. Meeder Asset Management Inc. bought a new stake in Exelixis during the first quarter worth about $170,000. Atlantic Trust Group LLC bought a new stake in Exelixis during the first quarter worth about $216,000. Finally, Klingenstein Fields & Co. LLC bought a new stake in Exelixis during the first quarter worth about $217,000. 79.93% of the stock is currently owned by institutional investors and hedge funds.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.